Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

SNDX.US Logo

SNDX.US - Current Price

$20.09

Company Information

▼
Company Name
Syndax Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US87164F1057
CIK: 0001395937
CUSIP: 87164F105
Currency: USD
Full Time Employees: 270
Phone: 781 419 1400
Website: https://syndax.com
Fiscal Year End: December
IPO Date: Mar 03, 2016
Description:

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Address:

730 Third Avenue, New York, NY, United States, 10017

Directors & Officers

▼
Name Title Year Born
Mr. Michael A. Metzger M.B.A. CEO & Director 1971
Mr. Keith Alan Goldan CPA CFO, Treasurer & Chief Accounting Officer 1971
Mr. Luke J. Albrecht J.D. Senior VP, General Counsel & Secretary 1979
Mr. Steven Closter Chief Commercial Officer 1969
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer 1969
Dr. Richard A. Heyman Ph.D. Co-Founder 1957
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board 1950
Dr. Michael Downes Ph.D. Co-Founder NA
Sharon Klahre Vice President of Investor Relations & Communications NA
Mr. Kevin McManus Chief People Officer 1969

Shares Statistics

▼
Shares Outstanding: 86.91M
Shares Float: 73.28M
% Insiders: 127.90%
% Institutions: 11,832.90%
Short % Float: 29.29%

Valuation Metrics

▼
Enterprise Value: $1.35B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $1.80B
EBITDA: $-306.90M
PEG Ratio: $0.00
Book Value: $1.33
Earnings/Share: $-3.60
Profit Margin: -279.93%
Operating Margin: -125.19%
ROA (TTM): -39.24%
ROE (TTM): -129.32%
Revenue (TTM): $111.30M
Revenue/Share (TTM): $1.29
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 267.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -0.59 N/A 10,000.00%
Sep 30, 2025 -0.70 -0.73 N/A 410.96%
Jun 30, 2025 -0.83 -1.01 N/A 1,782.18%
Mar 31, 2025 -0.98 -1.27 N/A 2,267.94%
Dec 31, 2024 -1.10 -0.23 N/A -38,055.92%
Sep 30, 2024 -0.98 -1.11 N/A 1,171.17%
Jun 30, 2024 -0.80 -0.91 N/A 1,208.79%
Mar 31, 2024 -0.85 -0.98 N/A 1,326.53%
Dec 31, 2023 -1.00 -0.99 N/A -101.01%
Sep 30, 2023 -0.73 -0.80 N/A 875.00%
Jun 30, 2023 -0.64 -0.73 N/A 1,232.88%
Mar 31, 2023 -0.59 -0.60 N/A 166.67%
Dec 31, 2022 -0.62 -0.65 N/A 461.54%
Sep 30, 2022 -0.58 -0.63 N/A 793.65%
Jun 30, 2022 -0.62 -0.64 N/A 312.50%
Mar 31, 2022 -0.63 -0.63 N/A 0.00%
Dec 31, 2021 1.81 0.28 N/A 54,642.86%
Sep 30, 2021 -0.40 -0.23 N/A -7,391.30%
Jun 30, 2021 -0.44 -0.71 N/A 3,802.82%
Mar 31, 2021 -0.54 -0.65 N/A 1,692.31%
Dec 31, 2020 -0.44 -0.49 N/A 1,020.41%
Sep 30, 2020 -0.46 -0.44 N/A -454.55%
Jun 30, 2020 -0.42 -0.45 N/A 666.67%
Mar 31, 2020 -0.56 -0.51 N/A -980.39%
Dec 31, 2019 -0.44 -0.43 N/A -232.56%
Sep 30, 2019 -0.41 -0.47 N/A 1,276.60%
Jun 30, 2019 -0.47 -0.43 N/A -930.23%
Mar 31, 2019 -0.53 -0.56 N/A 535.71%
Dec 31, 2018 -0.70 -0.67 N/A -447.76%
Sep 30, 2018 -0.68 -0.76 N/A 1,052.63%
Jun 30, 2018 -0.74 -0.87 N/A 1,494.25%
Mar 31, 2018 -0.79 -0.96 N/A 1,770.83%
Dec 31, 2017 -0.80 -0.78 N/A -256.41%
Sep 30, 2017 -0.68 -0.80 N/A 1,500.00%
Jun 30, 2017 -0.70 -0.83 N/A 1,566.27%
Mar 31, 2017 -0.71 -0.70 N/A -142.86%
Dec 31, 2016 -0.59 -0.73 N/A 1,917.81%
Sep 30, 2016 -0.84 -0.76 N/A -1,052.63%
Jun 30, 2016 -0.47 -0.53 N/A 1,132.08%
Mar 31, 2016 -2.85 -0.48 N/A -49,375.00%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $154.08M $N/A $724.82M $436.69M $288.12M
2023-12-31 $295.39M $N/A $612.88M $58.68M $554.20M
2022-12-31 $74.36M $N/A $497.24M $29.79M $467.45M
2021-12-31 $221.97M $N/A $449.66M $41.29M $408.37M
2020-12-31 $115.24M $N/A $300.61M $48.43M $252.19M
2019-12-31 $24.61M $N/A $63.53M $31.93M $31.60M
2018-12-31 $33.77M $N/A $83.94M $30.89M $53.05M
2017-12-31 $35.17M $N/A $137.19M $32.87M $104.32M
2016-12-31 $23.84M $N/A $109.01M $24.87M $84.14M
2015-12-31 $23.18M $N/A $89.90M $23.21M $66.70M
2014-12-31 $10.01M $N/A $12.82M $18.53M $-5.72M
2013-12-31 $10.10M $N/A $17.06M $5.21M $11.85M
2012-12-31 $537.00K $N/A $1.51M $30.80M $-29.29M
2011-12-31 $3.70M $N/A $4.79M $23.84M $-19.06M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 08, 2025 N/A N/A N/A N/A N/A N/A
Aug 18, 2025 N/A N/A N/A N/A N/A N/A
Aug 15, 2025 N/A N/A N/A N/A N/A N/A
Jul 16, 2025 N/A N/A N/A N/A N/A N/A
Jul 16, 2025 N/A N/A N/A N/A N/A N/A
Feb 10, 2025 N/A N/A N/A N/A N/A N/A
Feb 10, 2025 N/A N/A N/A N/A N/A N/A
Feb 10, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist